Novo Nordisk

The cost of Wegovy will soon be covered by Medicare, according to an announcement from the federal health insurance program for seniors on Thursday. And while that’s great news for people over 65 who want access to a medication that’s drawn so much attention for its ability to help with weight loss, there’s just one catch. Medicare will only pay if patients have potentially serious heart problems.The Fujifilm X100VI is the Most Fun I’ve Had With a Camera in YearsWegovy is the brand name of Novo Nordisk’s anti-obesity…

Novo Nordisk, the Danish drug maker whose fortunes have soared on the popularity of its GLP-1 agonist drugs, scored a long-sought label expansion for its weight-loss drug Wegovy on Friday, with FDA approving it to reduce the risk of major cardiovascular events in adults who are obese or overweight and have established cardiovascular disease. The approval is based on a nearly five-year-long study in which once-weekly injections of Wegovy were shown to reduce the overall risk of major adverse cardiac events—including…

Pharmaceutical company Eli Lilly is making a plea to some of its customers: stop hoarding our weight loss drugs. In a new Oscar-themed commercial set to run on TV this weekend, the drugmaker is not-so-subtly telling people to stay away from its new blockbuster medications if they’re only looking to lose a few pounds. These and similar drugs have continuously experienced shortages since their debut in recent years, with demand far outstripping supply.An AI That Helps You Get a Job? | AI UnlockedThe 30-second reverse…

There is now a regular deluge of new studies showing the potential widespread health benefits of GLP-1s, the class of drugs that encompasses diabetes and obesity treatments like Novo Nordisk’s Wegovy and Ozempic (which contain the active ingredient semaglutide) and Eli Lilly’s Zepbound and Mounjaro (active ingredient tirzepatide). From weight loss in obese patients, to protecting heart and cardiovascular health outcomes, to lowering blood pressure, combating fatty liver disease, and potentially even providing a boost to…

The newest obesity drug on the market, Eli Lilly’s tirzepatide, may also help keep people’s blood pressure in check, new research out Monday has shown. The study looked at clinical trial participants and found that people taking it experienced a drop in their systolic blood pressure on average compared to a placebo group over a six-month span. The research is the latest to indicate that a new group of obesity drugs can offer health benefits beyond weight loss.Alex Winter on Innovative Horror Movies Tirzepatide, developed…

So which one is it? Do these blockbuster medicines for diabetes and weight loss come with serious mental health risks, or could they actually be effective treatments for depression, bipolar disorder, Alzheimer’s disease, and other neurological conditions? It’s too early for a definitive answer, but ongoing research shows some early signs that these therapies, part of a drug class called GLP-1s, could be effective not just in trimming fat and protecting hearts. They might also help boost our brains.Wegovy and Ozempic, both…

Another year, another round of inscrutable price increases for many prescription drugs. Over 700 medicines are seeing their list prices shoot up this January, according to an analysis by the organization 46brooklyn Research. The average price increase is slightly below the trend of recent years, but includes popular drugs used for weight loss like Ozempic and Mounjaro.Remake this Sci-Fi Film with Peter Capaldi!The Ohio-based 46brooklyn is a nonprofit corporation that describes its purpose as seeking “to improve the…

Wegovy and similar weight loss drugs may cause more side effects than currently recognized. The Food and Drug Administration is now looking into whether these new generation obesity drugs can trigger hair loss, suicide ideation, and food aspiration, based on adverse event reports linked to their use. These reports are only intended to be a potential warning signal and do not prove causation, but the FDA could take further regulatory action should their investigation bear fruit, such as modifying the drugs’ labeling.Let’s…

Few prescription drugs have entered the public consciousness as abruptly as Ozempic and Wegovy have in recent years. Novo Nordisk’s brand-name medications have become as synonymous with weight loss as Viagra and Cialis are with erectile dysfunction. But while 2023 has made it clear that these and similar drugs really are the future of obesity treatment, it’s also shown that this future looks plenty messy—sometimes for reasons that have little to do with the drugs themselves.Let’s Eat a Chocolate Xbox…

Just about a year ago, the U.S. Food and Drug Administration approved Novo Nordisk’s blockbuster obesity drug, Wegovy, for use in teens ages 12 and up with a BMI at or above the 95th percentile for their age and sex. The decision came a little more than six months after the drug was approved for adults.You might ask, why the hurry? And, do teenagers really need weight-loss drugs? According to the CDC, 22% of adolescents aged 12 to 19 years have obesity. Since the 1980s, obesity rates have tripled in children and…